Pharmaceutical Research

, Volume 9, Issue 11, pp 1380–1385 | Cite as

An Alternative Approach for Assessment of Rate of Absorption in Bioequivalence Studies

  • Mei-Ling Chen
Article

Abstract

The partial area method was investigated for evaluation of equivalency in the rate of absorption of immediate release formulations. The applicability of the method was demonstrated with four drugs with different pharmacokinetic/pharmacodynamic characteristics. The confidence interval approach currently employed for bioequivalence determinations was applied to the relevant absorption parameters, including Cmax and partial AUCs. The method was found to be more discriminating than Cmax and/or Tmax in the evaluation of the absorption rate of drugs. The cutoff time or point for partial AUC calculation may vary with the type of drug under study, depending on its clinical use and onset of action. The method was shown to be useful in the assessment of rate of absorption in bioequivalence studies.

bioequivalence absorption rate partial AUC truncated AUC peak concentration time to peak 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    K. Khoo, M. Gibaldi, and R. K. Brazzell. Comparison of statistical moment parameters to Cmax and Tmax for detecting differences in in vivo dissolution rates. J. Pharm. Sci. 74(12):1340–1342 (1985).Google Scholar
  2. 2.
    A. J. Jackson and M.-L. Chen. Application of moment analysis in assessing rates of absorption for bioequivalency studies. J. Pharm. Sci. 76(l):6–9 (1987).Google Scholar
  3. 3.
    L. Aarons. Assessment of rate of absorption in bioequivalence studies. J. Pharm. Sci. 76(10):853–855 (1987).Google Scholar
  4. 4.
    P. Veng-Pedersen and L. G. Tillman. Center of gravity of drug level curves: A model-independent parameter useful in bioavailability studies. J. Pharm. Sci. 78(10):848–854 (1989).Google Scholar
  5. 5.
    Proceedings of Bio-International '89—Issues in the Evaluation of Bioavailability Data Session 1. Rate of Absorption in Bioequivalency Determinations, Toronto, Canada, Oct. 1–4, 1989.Google Scholar
  6. 6.
    M.-L. Chen. Assessment of Rate of Absorption in Bioequivalence Studies U.S. Food and Drug Administration, Generic Drugs Advisory Committee Meeting, Bethesda, MD, Sept. 26–27, 1991.Google Scholar
  7. 7.
    S. E. Rosenbaum, C. T. Rhodes, and C. Bon. Area under the curve estimation in bioequivalence studies. Drug Dev. Ind. Pharm. 16(1):157–163 (1990).Google Scholar
  8. 8.
    Antibiotic Residues in Milk, Dairy Products and Animal Tissues: Methods, Reports and Protocols U.S. Department of Health, Education and Welfare, Food and Drug Administration, Washington, DC, 1968, Part 1, Sect. 2, pp. 12–27.Google Scholar
  9. 9.
    J. L. Shimek, N. G. Rao, and S. K. Khalil. High-pressure liquid chromatographic determination of ibuprofen in plasma. J. Pharm. Sci. 70(5):514–516 (1980).Google Scholar
  10. 10.
    S. Sved, I. J. McGilveray, and N. Beaudoin. Assay of sulfonylureas in human plasma by high-performance liquid chromatography. J. Pharm. Sci. 65:1356 (1976).Google Scholar
  11. 11.
    S. I. Ankier, B. K. Martin, M. S. Rogers, P. K. Carpenter, and C. Graham. Trazodone—A new assay procedure and some pharmacokinetic parameters. Br. J. Clin. Pharmacol. 11:505–509 (1981).Google Scholar
  12. 12.
    M. Gibaldi and D. Perrier. Pharmacokinetics Marcel Dekker, New York, 1982.Google Scholar
  13. 13.
    D. J. Schuirmann. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokin. Biopharm. 15:657–680 (1987).Google Scholar
  14. 14.
    S. L. Nightingale and J. C. Morrison, Generic drugs and the prescribing physicians. JAMA 258(9):1200–1204 (1987).Google Scholar
  15. 15.
    A. J. Romero, C. Bon, E. Johnson, S. E. Rosenbaum, and C. T. Rhodes. Use and limitations of the truncated area under the curve in bioequivalence testing. Clin. Res. Prac. Drug Reg. Affairs 8(2):123–151 (1990).Google Scholar

Copyright information

© Plenum Publishing Corporation 1992

Authors and Affiliations

  • Mei-Ling Chen
    • 1
  1. 1.Division of Bioequivalence, HFD-655, Office of Generic Drugs (MPN II)Center for Drug Evaluation and Research, Food and Drug AdministrationRockville

Personalised recommendations